Stuart A. Arbuckle
Mr. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Commercial Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s reimbursement and access, sales, marketing, patient support, market research, commercial manufacturing, supply chain and other activities that support the approved use of Vertex’s cystic fibrosis medicines.
Mr. Arbuckle has more than 30 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim) injection and NEUPOGEN® (filgrastim), which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® (denosumab) injection and Nplate® (romiplostin) injection. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan, Asia, the Middle East and Africa.
Prior to these roles, Mr. Arbuckle spent 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.
Mr. Arbuckle currently serves as a member of Rhythm Pharmaceuticals and ImmunoGen's board of directors, as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO). He is also co-chair of the BIO Standing Committee on Access & Value.